Loading clinical trials...
Loading clinical trials...
A Phase 4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/Day MMX Mesalamine/Mesalazine Once Daily in Adult Subjects With Ulcerative Colitis
Conditions
Interventions
MMX mesalamine/ mesalazine
Locations
105
United States
Birmingham Gastroenterology Associates, PC
Birmingham, Alabama, United States
Advanced Clinical Research Institute
Anaheim, California, United States
Digestive & Liver Disease Specialists
Garden Grove, California, United States
Long Beach VA Medical Center
Long Beach, California, United States
Clinical Applications Laboratories, Inc.
San Diego, California, United States
Conneticut Gastroenterolgy Institute
Bristol, Connecticut, United States
Start Date
June 29, 2010
Primary Completion Date
December 7, 2012
Completion Date
December 7, 2012
Last Updated
June 9, 2021
NCT06372613
NCT07550673
NCT07374471
NCT06071312
NCT05739864
NCT04338204
Lead Sponsor
Shire
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions